# 2025年11月25日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 一种用于排除成人下呼吸道感染细菌性病因的血液四基因特征谱

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285807](https://pubmed.ncbi.nlm.nih.gov/41285807)
**期刊：** Nature communications
**PMID：** 41285807
**DOI：** 10.1038/s41467-025-65361-3

### 第一部分 原文与翻译

**英文原标题：** A four-gene signature from blood to exclude bacterial etiology of lower respiratory tract infection in adults.

**英文摘要原文：**
Unnecessary antibiotic use is a major driver of antimicrobial resistance, an urgent public health threat. Acute respiratory infection (ARI) is a leading cause of inappropriate antibiotic use, creating an unmet need for improved diagnostics to identify bacterial etiology in ARI. In this work we show a 4-gene signature defining the absence of bacterial ARI which may be useful for managing antibiotics in ARI. Hospitalized adults with ARI underwent comprehensive microbiologic testing and those with definitive viral (n = 280), bacterial (n = 129), or mixed viral-bacterial infection (n = 95) had whole blood RNA sequencing. A hard-thresholded, mostly relaxed, LASSO-constrained logistic regression model is used to select a parsimonious gene set (ITGB4, ITGA7, IFI27, FAM20A) highly capable of discriminating any bacterial from nonbacterial infection (cross-validated AUC = 0.90). The 4-gene signature is validated in five independent adult RNAseq cohorts (AUC = 0.89-0.98), two adult microarray cohorts (AUC = 0.73-0.90), and one pediatric pneumonia RNAseq cohort (AUC 0.74). Thresholding the 4-gene risk score to yield 90% sensitivity to detect bacterial infection results in 71% specificity and 91% negative predictive value.

**中文摘要译文：**
不必要的抗生素使用是抗菌素耐药性的主要驱动因素，而抗菌素耐药性是一个紧迫的公共卫生威胁。急性呼吸道感染（ARI）是抗生素不当使用的主要原因之一，因此，迫切需要改进诊断方法以识别ARI中的细菌性病因。在这项工作中，我们展示了一个能够确定不存在细菌性ARI的四基因特征谱，这可能有助于ARI患者的抗生素管理。研究对因ARI住院的成人进行了全面的微生物学检测，并对确诊为病毒性感染（n=280）、细菌性感染（n=129）或病毒-细菌混合感染（n=95）的患者进行了全血RNA测序。研究采用一种硬阈值、多数松弛、LASSO约束的逻辑回归模型，筛选出一个简约的基因集（ITGB4、ITGA7、IFI27、FAM20A），该基因集能高效区分细菌性与非细菌性感染（交叉验证AUC = 0.90）。这个四基因特征谱在五个独立的成人RNA测序队列（AUC = 0.89-0.98）、两个成人微阵列队列（AUC = 0.73-0.90）以及一个儿童肺炎RNA测序队列（AUC = 0.74）中得到了验证。将该四基因风险评分的阈值设定在能够达到90%的细菌性感染检测灵敏度时，其特异性为71%，阴性预测值为91%。

### 第二部分 AI 大师评价

本研究旨在开发一种基于血液的基因特征谱，以精准区分成人下呼吸道感染的细菌性与非细菌性病因，从而应对抗生素滥用这一公共卫生挑战。研究人员通过对患者全血RNA测序数据应用LASSO回归模型，成功筛选出一个由四个基因（ITGB4, ITGA7, IFI27, FAM20A）组成的诊断标志物。该基因特征谱在多个独立队列中展现了出色的诊断效能，尤其在排除细菌感染方面具有高达91%的阴性预测值，为临床安全地停用非必要抗生素提供了有力证据。这项工作的创新性在于提供了一种快速、基于宿主反应的诊断工具，对于指导临床合理使用抗生素、延缓耐药性发展具有重大的潜在价值。

---

## 2. 通过多组学研究中目标导向的亚群识别方法推导脓毒症共识分型

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41285725](https://pubmed.ncbi.nlm.nih.gov/41285725)
**期刊：** Nature communications
**PMID：** 41285725
**DOI：** 10.1038/s41467-025-65271-4

### 第一部分 原文与翻译

**英文原标题：** Deriving consensus sepsis clusters via goal-directed subgroup identification in multi-omics study.

**英文摘要原文：**
Sepsis, a syndrome of life-threatening organ dysfunction caused by dysregulated host responses to infection, exhibits profound pathobiological heterogeneity, hindering the development of effective therapies. Current subtyping approaches, often reliant on single-omics data or unsupervised clustering, yield poorly reproducible and therapeutically misaligned classifications. Here, we introduce a goal-directed subgroup identification (GD-SI) framework that optimizes patient stratification for differential treatment responses, integrating longitudinal multi-omics data (transcriptomic, proteomic, metabolomic, phenomic) from 1327 subjects across 43 hospitals. While supervised multi-omics integration frameworks (e.g., DIABLO) effectively capture shared biological signals, our approach anchors subgroup discovery directly to treatment-effect optimization. This strategy achieves substantial cross-omic concordance and, crucially, generalizes to predict differential treatment response across international critical care databases. Patients stratified by GD-SI-derived benefit scores for restrictive versus liberal fluid resuscitation exhibited marked survival differences, with similar advantages observed for ulinastatin immunomodulation. External validations in MIMIC-IV and ZiGongDB confirm prognostic generalizability. This framework reconciles biological heterogeneity with clinical actionability, offering a scalable infrastructure for precision trial design and personalized sepsis management. Our findings underscore the translational potential of omics-driven, goal-directed stratification to overcome decades of therapeutic stagnation in critical care.

**中文摘要译文：**
脓毒症是由宿主对感染的反应失调所引起的危及生命的器官功能障碍综合征，其病理生物学具有显著的异质性，这阻碍了有效疗法的开发。目前的亚型分类方法通常依赖于单组学数据或无监督聚类，其结果往往可重复性差，且与治疗策略不一致。在此，我们引入一种目标导向的亚群识别（GD-SI）框架，该框架整合了来自43家医院1327名受试者的纵向多组学数据（转录组、蛋白质组、代谢组、表型组），旨在优化患者分层以实现差异化治疗反应。尽管监督性多组学整合框架（如DIABLO）能有效捕捉共享的生物学信号，但我们的方法将亚群发现直接定位于治疗效果的优化。该策略实现了显著的跨组学一致性，并且至关重要的是，它能够泛化应用于预测国际重症监护数据库中的差异化治疗反应。根据GD-SI衍生的限制性与开放性液体复苏获益评分进行分层的患者，其生存率表现出显著差异，在乌司他丁免疫调节治疗中也观察到类似的优势。在MIMIC-IV和ZiGongDB数据库中的外部验证证实了该模型的预后泛化能力。该框架将生物学异质性与临床可操作性相结合，为精准试验设计和脓毒症的个性化管理提供了一个可扩展的基础设施。我们的研究结果强调了由组学驱动、目标导向的分层方法在克服重症监护领域数十年来治疗停滞方面的转化潜力。

### 第二部分 AI 大师评价

本研究的核心目的在于解决脓毒症因其高度异质性而导致的治疗困境，为此开发并验证了一种创新的“目标导向亚群识别”（GD-SI）框架。该方法巧妙地整合多组学数据，不再局限于传统的无监督聚类，而是直接以优化不同治疗方案（如液体复苏策略）的疗效为目标进行患者分层。其关键发现是，通过此框架识别的患者亚群在接受特定干预后表现出显著的生存差异，且该模型在外部数据库中得到验证，展示了良好的泛化能力与临床可操作性。这项工作为实现脓毒症的精准治疗和个性化临床试验设计提供了强有力的工具，具有重大的临床转化潜力。

---

## 3. 呼吸道合胞病毒疫苗在美国退伍军人群体中有效性的持久性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284307](https://pubmed.ncbi.nlm.nih.gov/41284307)
**期刊：** JAMA internal medicine
**PMID：** 41284307
**DOI：** 10.1001/jamainternmed.2025.6355

### 第一部分 原文与翻译

**英文原标题：** Durability of Respiratory Syncytial Virus Vaccine Effectiveness Among US Veterans.

**英文摘要原文：**
IMPORTANCE: A single respiratory syncytial virus (RSV) vaccine dose is recommended for older adults and persons at increased risk for severe RSV. Clinical information on the long-term effectiveness of RSV vaccines is needed.

OBJECTIVE: To determine the effectiveness of RSV vaccination over 2 respiratory illness seasons.

DESIGN, SETTING, AND PARTICIPANTS: This target trial emulation used data from the Veterans Health Administration and included veterans 60 years and older who were eligible for RSV vaccination from September 2023 to March 2024.

EXPOSURE: A single dose of a recombinant stabilized prefusion F protein RSV vaccine vs no RSV vaccination.

MAIN OUTCOMES AND MEASURES: Eligible vaccine recipients were matched with up to 4 unvaccinated individuals in 7 monthly, nested sequential trials from September 1, 2023, to March 31, 2024. Outcomes were ascertained through March 31, 2025. The primary outcome was any positive RSV test result from day 14 following the matched index date. Secondary outcomes included RSV-associated emergency department or urgent care visits, hospitalizations, or intensive care unit admissions. Vaccine effectiveness was estimated as 100 × (1 - risk ratio).

RESULTS: A total of 288 111 vaccinated individuals were matched to 1 075 893 unique control individuals, weighted equally to represent 576 222 individuals, and followed up for a median of 15.8 months (IQR, 14.5-17.0). Across both groups, 544 364 of 576 222 veterans (94.5%) were male, and the median age was 76.1 years (IQR, 71.6-80.0). Vaccine effectiveness against documented RSV infections decreased from 82.5% (95% CI, 77.5%-86.9%) over 0 to 1 month to 59.4% (95% CI, 55.6%-63.5%) over 0 to 18 months of follow-up. During the same period, effectiveness decreased from 84.9% (95% CI, 78.4%-90.2%) to 60.5% (95% CI, 56.4%-65.7%) for emergency visits and 88.9% (95% CI, 77.9%-95.7%) to 57.3% (95% CI, 47.3%-66.4%) for hospitalizations and was 92.5% (95% CI, 61.1%-100.0%) and 71.9% (95% CI, 42.8%-90.0%) for intensive care unit admissions. Among immunocompromised individuals, protection against documented infections decreased from 75.2% (95% CI, 52.5%-89.3%) to 39.7% (95% CI, 23.9%-52.7%).

CONCLUSIONS AND RELEVANCE: The study found that RSV vaccination was effective in preventing RSV illness and associated health care use but that protection decreased over 2 seasons. Reductions were most notable among immunocompromised persons, suggesting the need to review whether additional vaccine doses may benefit certain risk groups.

**中文摘要译文：**
重要性: 目前推荐老年人及重症RSV高风险人群接种单剂呼吸道合胞病毒（RSV）疫苗。临床上需要关于RSV疫苗长期有效性的信息。

目的: 旨在确定RSV疫苗接种在两个呼吸道疾病季节中的有效性。

设计、地点与参与者: 本研究采用目标试验模拟设计，使用了退伍军人健康管理局的数据，纳入了2023年9月至2024年3月期间符合RSV疫苗接种条件的60岁及以上退伍军人。

暴露: 接种单剂重组稳定型融合前F蛋白RSV疫苗与未接种RSV疫苗进行比较。

主要结局与测量指标: 在2023年9月1日至2024年3月31日期间的7个按月进行的嵌套序贯试验中，将符合条件的疫苗接种者与最多4名未接种者进行匹配。结局评估持续至2025年3月31日。主要结局为匹配索引日后第14天起的任何RSV检测阳性结果。次要结局包括与RSV相关的急诊或紧急护理就诊、住院或重症监护室收治。疫苗有效性估算公式为100 × (1 - 风险比)。

结果: 总计288,111名接种者与1,075,893名独立未接种对照者相匹配，经等权重处理后代表576,222人，中位随访时间为15.8个月（IQR, 14.5-17.0）。在两组中，576,222名退伍军人中有544,364名（94.5%）为男性，中位年龄为76.1岁（IQR, 71.6-80.0）。在0至18个月的随访期内，疫苗对有记录的RSV感染的有效性从0至1个月的82.5%（95% CI, 77.5%-86.9%）下降至59.4%（95% CI, 55.6%-63.5%）。同期，对于急诊就诊的有效性从84.9%（95% CI, 78.4%-90.2%）降至60.5%（95% CI, 56.4%-65.7%），对于住院的有效性从88.9%（95% CI, 77.9%-95.7%）降至57.3%（95% CI, 47.3%-66.4%），对于重症监护室收治的有效性则分别为92.5%（95% CI, 61.1%-100.0%）和71.9%（95% CI, 42.8%-90.0%）。在免疫功能低下个体中，对有记录感染的保护作用从75.2%（95% CI, 52.5%-89.3%）降至39.7%（95% CI, 23.9%-52.7%）。

结论与相关性: 研究发现，RSV疫苗接种能有效预防RSV疾病及相关的医疗资源使用，但其保护作用在两个季节内有所下降。这种下降在免疫功能低下人群中尤为显著，提示需要重新评估额外剂次的疫苗接种是否能使特定风险群体受益。

### 第二部分 AI 大师评价

本研究通过一项大规模的目标试验模拟，利用美国退伍军人的真实世界数据，旨在评估RSV疫苗在两个呼吸道疾病季节中的长期有效性。研究关键发现，单剂疫苗在初期能高效预防RSV感染及相关重症，但其保护效果随时间显著下降，尤其在免疫功能低下人群中。这项研究为理解RSV疫苗保护持久性提供了宝贵的临床证据，对其在老年人和高风险群体的长期免疫策略（如是否需要加强针）具有重要的指导意义和临床价值。

---

## 4. 吸入器价格上限——缺乏改革的补丁式进展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284270](https://pubmed.ncbi.nlm.nih.gov/41284270)
**期刊：** JAMA internal medicine
**PMID：** 41284270
**DOI：** 10.1001/jamainternmed.2025.6321

### 第一部分 原文与翻译

**英文原标题：** Inhaler Price Caps-Patchwork Progress Without Reform.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无可用摘要。

### 第二部分 AI 大师评价

本文似乎是一篇关于美国药物定价政策的评论或观点文章，重点关注吸入器价格上限政策。根据标题推断，作者认为，尽管为吸入器设定价格上限取得了一些零散的进展，但这并非系统性改革，只是治标不治本的“补丁式”措施。该文的价值在于揭示了当前药品控价策略的局限性，并可能呼吁进行更深层次的医疗保健系统改革，以真正解决处方药价格高昂的根本问题。

---

## 5. 机械通气患者中强化早期活动的个体化治疗效应：TEAM试验的二次分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284015](https://pubmed.ncbi.nlm.nih.gov/41284015)
**期刊：** Intensive care medicine
**PMID：** 41284015
**DOI：** 10.1007/s00134-025-08217-0

### 第一部分 原文与翻译

**英文原标题：** Individualised treatment effects of enhanced early mobilisation in mechanically ventilated patients: a secondary analysis of the TEAM trial.

**英文摘要原文：**
PURPOSE: Benefit or harm from early mobilisation (EM) in mechanically ventilated patients may vary by individual patient characteristics. We used machine learning to predict individualised treatment effects (ITEs) in the "Early Active Mobilization during Mechanical Ventilation in the ICU" (TEAM) trial.

METHODS: This was a secondary analysis of the TEAM trial using a causal inference approach to estimate ITEs, which compared enhanced EM to usual care EM. Baseline variables in the original publication were used as predictor variables. The primary outcome was death by day 180. The dataset was randomly split into two halves (train and test) by site. In the training data, fivefold cross-validation was used to compare six candidate machine learning algorithms. The best-performing model was evaluated in the test dataset. Patients were stratified into tertiles based on predicted ITEs, reflecting estimated benefit, no effect or harm.

RESULTS: We included 687 patients from 40 sites, and 141 (20.5%) patients died by day 180. Predicted ITEs in the test cohort ranged from an absolute 34.0% reduction to a 39.3% increase in mortality with enhanced EM. The interaction term between the model predictions and treatment assignment demonstrated significant heterogeneity of treatment effect (p = 0.006). Patients predicted to respond poorly to enhanced EM therapy were more likely to receive vasopressors, have diabetes and have lower RASS scores at baseline, compared to patients predicted to have benefit.

CONCLUSION: Using baseline characteristics, a machine learning model identified patients with estimated benefit or harm with enhanced EM. Future testing of a personalised approach to mobilisation in the ICU is warranted.

**中文摘要译文：**
目的：机械通气患者从早期活动（EM）中获益或受损可能因个体患者特征而异。我们利用机器学习在“ICU机械通气期间的早期主动活动”（TEAM）试验中预测了个体化治疗效应（ITEs）。

方法：这是一项TEAM试验的二次分析，采用因果推断方法来评估ITEs，该分析比较了强化EM与常规护理EM。原始研究发表中的基线变量被用作预测变量。主要结局是180天内的死亡。数据集按研究中心被随机分为两半（训练集和测试集）。在训练数据中，使用五折交叉验证来比较六种候选机器学习算法。表现最佳的模型在测试数据集中进行了评估。根据预测的ITEs将患者分层为三分位数，分别反映预估的获益、无效应或有害。

结果：我们纳入了来自40个研究中心的687名患者，其中141名（20.5%）在180天内死亡。在测试队列中，预测的ITEs显示，接受强化EM的患者死亡率绝对变化范围为降低34.0%至增加39.3%。模型预测与治疗分配之间的交互项显示出显著的治疗效应异质性（p = 0.006）。与预测将获益的患者相比，那些预测对强化EM治疗反应不佳的患者在基线时更可能接受血管加压药、患有糖尿病且RASS评分较低。

结论：利用基线特征，一个机器学习模型识别出了可能从强化EM中获益或受损的患者。未来有必要对ICU中个性化的活动方案进行检验。

### 第二部分 AI 大师评价

该研究基于TEAM试验数据，创新性地运用机器学习方法，旨在预测并识别哪些机械通气患者能从强化早期活动中真正获益或可能受损。其核心发现是，通过分析患者的基线特征，模型能有效区分出治疗效应的异质性，并描绘出潜在受益和高风险患者的临床画像。这项研究的价值在于，它挑战了“一刀切”的康复策略，为在重症监护领域实现精准、个体化的早期活动方案提供了强有力的证据和方法学基础，为未来临床决策的个体化提供了新思路。

---

## 6. 谵妄的诊断：生物标志物的新兴作用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41284013](https://pubmed.ncbi.nlm.nih.gov/41284013)
**期刊：** Intensive care medicine
**PMID：** 41284013
**DOI：** 10.1007/s00134-025-08230-3

### 第一部分 原文与翻译

**英文原标题：** Diagnosing delirium: the emerging role of biomarkers.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
暂无摘要。

### 第二部分 AI 大师评价

该文献标题明确指出了其核心内容，即探讨生物标志物在谵妄诊断中的新兴作用。虽然缺少摘要，但可推断本文可能是一篇综述或述评，旨在系统性总结用于辅助诊断谵妄的各类生物标志物的研究进展。其核心价值在于强调了谵妄诊断正从传统临床评估向量化、客观化的生物学指标转变，这有望为改善目前诊断的延迟和不确定性提供新途径。此文对于推动开发更快速、精准的谵妄诊断工具具有重要的启发意义，可能对未来重症监护领域的临床实践产生影响。

---

## 7. 较高 vs. 较低血压目标对血管扩张性休克患者死亡率的影响：一项更新的系统综述与荟萃分析。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41276856](https://pubmed.ncbi.nlm.nih.gov/41276856)
**期刊：** Critical care (London, England)
**PMID：** 41276856
**DOI：** 10.1186/s13054-025-05769-x

### 第一部分 原文与翻译

**英文原标题：** Mortality effect of higher versus lower blood pressure targets in vasodilatory shock: an updated systematic review and meta-analysis.

**英文摘要原文：**
OBJECTIVE: To determine the impact of higher versus lower mean arterial pressure (MAP) targets on mortality and other outcomes in patients with vasodilatory shock.

DESIGN: A systematic review and meta-analysis of randomised controlled trials (RCTs) following PRISMA guidelines with the protocol preregistered with PROSPERO (CRD420251087844).

DATA SOURCES: PubMed, Embase, CENTRAL, and Scopus from their inception until July 2025.

METHODS: This review included RCTs that compared a higher MAP target arm, typically 80±5 mmHg or the physiologically higher target arm within the trial, to a lower target arm (generally 65±5 mmHg) in adult patients with vasodilatory shock. The primary outcome was all-cause mortality. The analysis utilised random-effects models, subgroup analyses, and Bayesian methods.

RESULTS: Four RCTs with a total of 3,873 patients were included. A higher MAP target was associated with a 10% increase in 28-day mortality (RR 1.10, 95% CI 1.01-1.19; P=0.03). A similar trend toward increased 90-day mortality was observed, with a risk ratio of 1.10 (95% CI 1.00-1.22; P=0.05). Subgroup analyses revealed no benefit from higher targets for any patient group, including those with advanced age or chronic hypertension. A higher MAP target was also linked to fewer RRT-free days (mean difference -1.64, 95% CI -3.05 to -0.23; P = 0.02) and a greater risk of arrhythmia (RR 1.32, 95% CI 1.01-1.72; P=0.04). The Bayesian analysis corroborated these findings, revealing a high posterior probability of harm (97.8% for 28-day mortality and 98.7% for 90-day mortality).

CONCLUSIONS: In patients with vasodilatory shock, universal high MAP targets are associated with increased mortality compared with lower targets, with moderate certainty. These results should encourage the adoption of lower MAP targets and highlight the importance of avoiding the potential harm associated with excessive vasopressor use. Future research should focus on individualised blood pressure rather than fixed targets.

**中文摘要译文：**
目的：旨在明确血管扩张性休克患者中，采用较高与较低平均动脉压（MAP）目标对其死亡率及其他结局的影响。

设计：本研究是一项遵循PRISMA指南的随机对照试验（RCTs）的系统综述与荟萃分析，其方案已在PROSPERO预先注册（CRD420251087844）。

数据来源：检索了PubMed、Embase、CENTRAL和Scopus数据库，时间范围从建库至2025年7月。

方法：本综述纳入了在成年血管扩张性休克患者中，比较较高MAP目标组（通常为80±5 mmHg或试验中生理上较高的目标组）与较低目标组（通常为65±5 mmHg）的RCTs。主要结局为全因死亡率。分析采用了随机效应模型、亚组分析和贝叶斯方法。

结果：共纳入4项RCTs，涉及3873名患者。较高的MAP目标与28天死亡率增加10%相关（RR 1.10, 95% CI 1.01-1.19; P=0.03）。在90天死亡率方面也观察到相似的增加趋势，风险比为1.10（95% CI 1.00-1.22; P=0.05）。亚组分析显示，对于任何患者群体（包括高龄或慢性高血压患者），较高的目标均未带来益处。较高的MAP目标还与更少的无肾脏替代治疗（RRT）天数（平均差 -1.64, 95% CI -3.05 至 -0.23; P = 0.02）以及更高的心律失常风险（RR 1.32, 95% CI 1.01-1.72; P=0.04）相关。贝叶斯分析证实了这些发现，显示出较高的事后伤害概率（28天死亡率为97.8%，90天死亡率为98.7%）。

结论：在中等确定性的证据下，对于血管扩张性休克患者，与较低目标相比，普遍采用较高的MAP目标与死亡率增加相关。这些结果应鼓励临床采纳较低的MAP目标，并强调避免因过度使用血管升压药而造成潜在伤害的重要性。未来的研究应侧重于个体化的血压管理，而非固定的目标值。

### 第二部分 AI 大师评价

本研究通过对4项随机对照试验的系统回顾与荟萃分析，旨在评估血管扩张性休克患者中不同平均动脉压（MAP）目标对死亡率的影响。核心发现明确指出，与常规的较低目标（约65 mmHg）相比，追求较高的MAP目标（约80 mmHg）不仅未能带来生存获益，反而显著增加了28天和90天死亡风险，并与心律失常等不良事件增多相关。该研究以中等质量的证据，有力地挑战了在休克复苏中“血压越高越好”的传统观念，为临床实践中采纳更低的血压目标、避免过度使用升压药物提供了关键依据，并指明了个体化血压管理是未来的重要研究方向。

---

速递结束，祝您工作愉快！